Medical Devices

Lindsay Boyle's move to Blink Anesthesia signals a massive commercial shift as new clinical guidelines force hospitals to upgrade surgical monitoring tech.

As biopharma pivots to high-dose subcutaneous therapies, conventional delivery systems are hitting a mechanical wall. Early 'systems thinking' is the new mandate.

As hospitals face crushing margin pressures, a newly independent Ally Technical secures FFL Partners' backing to disrupt the OEM medical device repair monopoly.

AIRS Medical's FDA-cleared SwiftSight transforms MRI body composition into a sub-five-minute, radiation-free scan, unlocking new revenue for imaging centers.

Datasea’s FY2026 results reveal a bold strategy: slashing low-margin revenue by 43% to drive a 70% gross profit increase and fund a pivot to acoustic AI.

Cuprina Holdings is acquiring a seven-clinic healthcare group in Singapore, transforming the biomedical developer into a vertically integrated care provider.

As Resmed prepares to report its Q1 FY2027 earnings, investors are watching how the medical device giant navigates GLP-1 disruptions and AI-driven growth.

The AMA's approval of Category I codes for single-lead neurostimulators marks a massive operational shift for sleep apnea care and clinical adoption.

As life science supply chains face mounting risks, manufacturers are realizing that a simple labeling error can halt multi-million-dollar production lines.

BioCardia’s revised FDA submission for its Helix catheter could set a new regulatory standard and unlock lucrative biopharma partnerships.

SINTX Technologies smashed Q3 guidance with a pivot to aerospace ceramics, triggering a warrant call that forces investors to weigh dilution against growth.

By appointing a single president for the US and Canada, the German optics giant is positioning itself to capitalize on North America's industrial reshoring.

A new peer-reviewed study validates RenovoRx's targeted catheter platform, offering a strategic bridge as the company approaches its 2027 Phase III readout.

ViCentra's latest real-world data reveals exceptional glucose control, positioning its design-first Kaleido pump to challenge major medtech incumbents.

Johnson & Johnson’s new eye health campaign highlights a hidden menopause symptom, revealing a calculated push to capture a booming demographic market.

New clinical data reveals how dynamic perfusion technology is preventing catastrophic bedsores in critically ill ECMO patients and saving hospitals millions.

A new campaign highlights how pre-packaging surgical trays to save ten minutes of prep time could alleviate the structural crisis facing European hospitals.

By offloading its capital-heavy rental unit to Rotech, Inogen is rewriting its business model to focus on high-margin respiratory innovation and scale.

Ceribell's latest FDA clearance for age-agnostic, AI-driven EEG trending is democratizing brain monitoring and redefining the medtech SaaS playbook.

As Chinese medtech giant Sinocare unveils its chronic disease portfolio in Milan, the push to decentralize diagnostics from hospitals to pharmacies accelerates.